Menu
In-Depth

Drug policies take on less prominence

It wasn’t that long ago when Bud Selig was tagged as “The Steroid Commissioner,” and it was widely assumed that moniker would follow him to the grave. But just barely three years since the public release of the infamous Mitchell Report, the issue has largely receded from public view.

Just three major league players have failed a test for performance-enhancing drugs since the start of the 2009 season, the most prominent being slugger Manny Ramirez, then of the Los Angeles Dodgers. The number of minor leaguers implicated over the same time is more than 160. But in general, there is a growing feeling that baseball’s numerous corrections to its drug policies over the past half-decade are beginning to have their intended effects.

The issue will take on less prominence during the coming labor negotiations compared with prior rounds, in part because both sides have regularly addressed the drug program since the Mitchell Report’s release. In addition to measures calling for a thorough annual review, new substances that become federally banned automatically become prohibited within baseball’s drug program.

“We’ve been revisiting this topic regularly. That was one of the big positive outcomes of the Mitchell Report,” said Rob Manfred, MLB executive vice president for labor relations and human resources. “So, yes, it’s fair to say, this one relative to some other issues on the table will not be as major.”

Human growth hormone, however, is still a particularly thorny problem. A scientifically validated and scalable urine test for HGH remains elusive, despite plenty of attention and money, including from MLB, being thrown at the problem.

MLB last year began a blood test for HGH in the minors, where there is no players union and such matters are not subject to collective bargaining, and it’s likely the issue will be at least discussed for the major league level. The MLBPA, however, has historically shown great resistance to any sort of blood collection for testing purposes, with concerns including player safety and residual effects upon on-field performance.

SBJ Morning Buzzcast: May 3, 2024

Seismic change coming for NCAA? Churchill Downs rolls out major premium build out and Jeff Pash, a key advisor to Roger Goodell, steps down

Learfield's Cory Moss, MASN/ESPN's Ben McDonald, and Canelo

On this week’s pod, SBJ’s Austin Karp has two Big Get interviews. The first is with Learfield's Cory Moss as he talks about his company’s collaboration on EA Sports College Football. Later in the show, we hear from MASN/ESPN baseball analyst Ben McDonald on how he sees the college and professional baseball scene shaking out. SBJ’s Adam Stern shares his thoughts on the upcoming Canelo-Mungia bout on Prime Video and DAZN.

SBJ I Factor: Molly Mazzolini

SBJ I Factor features an interview with Molly Mazzolini. Elevate's Senior Operating Advisor – Design + Strategic Alliances chats with SBJ’s Ross Nethery about the power of taking chances. Mazzolini is a member of the SBJ Game Changers Class of 2016. She shares stories of her career including co-founding sports design consultancy Infinite Scale career journey and how a chance encounter while working at a stationery store launched her career in the sports industry. SBJ I Factor is a monthly podcast offering interviews with sports executives who have been recipients of one of the magazine’s awards.

Shareable URL copied to clipboard!

https://www.sportsbusinessjournal.com/Journal/Issues/2011/04/04/In-Depth/Drug-testing.aspx

Sorry, something went wrong with the copy but here is the link for you.

https://www.sportsbusinessjournal.com/Journal/Issues/2011/04/04/In-Depth/Drug-testing.aspx

CLOSE